inhibitor nedd8-activating enzyme new approach treat cancer 
clinical development inhibitor cellular proteasome function suggests compounds targeting components ubiquitin-proteasome system might prove useful treatment human malignancies nedd8-activating enzyme nae essential component nedd8 conjugation pathway controls activity cullin-ring subtype ubiquitin ligases thereby regulating turnover subset proteins upstream proteasome substrates cullin-ring ligases important roles cellular processes associated cancer cell growth survival pathways describe mln4924 potent selective inhibitor nae mln4924 disrupts cullin-ring ligase-mediated protein turnover leading apoptotic death human tumour cells new mechanism action deregulation s-phase dna synthesis mln4924 suppressed growth human tumour xenografts mice compound exposures well tolerated data suggest nae inhibitors may hold promise treatment cancer 
